clonoSEQ, from Adaptive Biotechnologies, can detect 1 cancer cell among a million healthy cells. Adaptive Biotechnologies received its third approval from the FDA for the use of its next-generation ...
This systematic review focusing on the targeted therapy era found solid associations between measurable residual disease (MRD) and clinical outcomes in patients with chronic lymphocytic leukemia.
According to the World Health Organization, cancer diagnoses remain a leading cause of death. However, scientific and medical communities have improved clinical outcomes for many people, transforming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results